阿诺医药(Adlai Nortye)今日正式披露,已向澳大利亚相关监管机构提交了关于其Pan-Ras(on)抑制剂ADC AN4035的I期临床试验通知。与此同时,该研究也获得了澳大利亚人类研究伦理委员会(Hrec)的批准。此举标志着这位创新药企在推进其前沿管线方面迈出关键一步。
阿诺医药(Adlai Nortye)今日正式披露,已向澳大利亚相关监管机构提交了关于其Pan-Ras(on)抑制剂ADC AN4035的I期临床试验通知。与此同时,该研究也获得了澳大利亚人类研究伦理委员会(Hrec)的批准。此举标志着这位创新药企在推进其前沿管线方面迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.